NextCure  Inc (NXTC)

NASDAQ
1.460
+0.060(+4.29%)
  • Volume:
    73,800
  • Day's Range:
    1.370 - 1.490
  • 52 wk Range:
    1.260 - 6.480

NXTC Overview

Prev. Close
1.4
Day's Range
1.37-1.49
Revenue
-
Open
1.38
52 wk Range
1.26-6.48
EPS
-2.68
Volume
73,800
Market Cap
40.36M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
113,868
P/E Ratio
-0.60
Beta
0.128
1-Year Change
-75.52%
Shares Outstanding
27,774,536
Next Earnings Date
Mar 02, 2023
What is your sentiment on NextCure?
or
Vote to see community's results!

NextCure  Inc News

NextCure  Inc Analysis

NextCure  Inc Company Profile

NextCure  Inc Company Profile

Employees
87

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.

Read More

Analyst Price Target

Average6.000 (+310.96% Upside)
High8
Low4
Price1.46
No. of Analysts7
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyBuySellStrong Sell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong SellStrong Sell
SummaryStrong BuyStrong BuyStrong BuyStrong SellStrong Sell
  • Whats the story on this company? I just bought in at $9.27. Its been hit hard but maybe due for a comeback?
    1
    • lol
      0
      • glad u r laughing ! I am LOL now, since I can buy it this cheap now
        0